- Home
- PBYI vs AMRN Comparison
PBYI vs AMRN Comparison
Compare PBYI & AMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PBYI | AMRN |
|---|---|---|
| Founded | 2010 | 1989 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 364.9M | 342.8M |
| IPO Year | 2011 | 1998 |
Fundamental Metrics
Financial Performance| Metric | PBYI | AMRN |
|---|---|---|
| Price | $8.07 | $14.71 |
| Analyst Decision | | Strong Sell |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | ★ 374.7K | 85.4K |
| Earning Date | 05-07-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 55.00 |
| EPS | N/A | ★ N/A |
| Revenue | $27,685,000.00 | ★ $181,104,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1.26 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 39.22 |
| 52 Week Low | $3.03 | $12.96 |
| 52 Week High | $8.44 | $20.90 |
Technical Indicators
Market Signals| Indicator | PBYI | AMRN |
|---|---|---|
| Relative Strength Index (RSI) | 56.00 | 40.15 |
| Support Level | $6.50 | $13.58 |
| Resistance Level | $8.42 | $15.39 |
| Average True Range (ATR) | 0.41 | 0.70 |
| MACD | -0.02 | -0.19 |
| Stochastic Oscillator | 47.13 | 5.06 |
Price Performance
Historical ComparisonAbout PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also, it is developing Alisertib, a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis, resulting in apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
About AMRN Amarin Corporation plc
Amarin Corp PLC is a pharmaceutical company. The company is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa. The company focuses on treatments to stop cardiovascular disease causing death, by providing patients, doctors and investors with reliable cardiovascular treatment options. Geographically, the company derives maximum revenue from United States.